pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
Quick answer
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorectal Cancer (CRC), Hyperlipidemia. NovaPharmaNews links 96 clinical program(s), 10 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (51), phase 2 (26), phase 1 (17).
Company snapshot
Amgen maintains 96 tracked programs across Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorectal Cancer (CRC), Hyperlipidemia, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Dyslipidemia, Asthma, Relapsed/Refractory Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Ulcerative Colitis (UC). Momentum score: 45/100 (30-day
- 19 approved product(s) across US/EU regulatory metadata.
- 96 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Amgen. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow
- approval
Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors
- approval
FDA Shakeup: Høeg's Departure and Amgen Drug Controversy
- trial_data
MariTide Phase 2 obesity data show up to 20% weight loss at one year
- trial_data
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Recent coverage
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.
FDA Shakeup: Høeg's Departure and Amgen Drug Controversy
The FDA's dismissal of acting CDER director Tracy Høeg and the revelation of 20 patient deaths linked to Amgen's Tavneos in Japan create a dual crisis of regulatory leadership and drug safety. This analysis provides key takeaways, a timeline of events, and strategic implications for pharmaceutical BD and regulatory teams.
Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors
Recent leadership transitions at Amgen and Zai Lab signal potential shifts in strategic direction and operational focus. Understanding these changes is crucial for pharmaceutical business development, investment, and regulatory teams.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- approved
Congress & presentations
Momentum
Proprietary activity score for Amgen.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Amgen.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Amgen?
-
Is Amgen publicly traded?
-
What drugs does Amgen develop or market?
-
What are the latest developments for Amgen?
-
What therapeutic areas does Amgen focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
Amgen maintains 96 tracked programs across Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorectal Cancer (CRC), Hyperlipidemia, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Dyslipidemia, Asthma, Relapsed/Refractory Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Ulcerative Colitis (UC). Momentum score: 45/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: Thousand Oaks USA. Ticker: E44D425.
Pipeline programs
Denosumab — phase phase_3, status completed. Indication: Cancer. Next milestone: not disclosed (TBD).
Dexamethasone — phase phase_3, status completed. Indication: Relapsed Multiple Myeloma. Next milestone: not disclosed (TBD).
Carfilzomib — phase phase_3, status completed. Indication: Multiple Myeloma. Next milestone: not disclosed (TBD).
Darbepoetin alfa — phase phase_3, status terminated. Indication: Non-Small Cell Lung Cancer. Next milestone: not disclosed (TBD).
ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL — phase phase_3, status active. Indication: Metastatic castration-resistant prostate cancer (mCRPC). Next milestone: not disclosed (TBD).
Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection — phase phase_3, status active. Indication: Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer. Next milestone: not disclosed (TBD).
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy — phase phase_3, status active. Indication: Early-stage Non-squamous Non-small Cell Lung Cancer. Next milestone: not disclosed (TBD).
Atorvastatin — phase phase_3, status completed. Indication: Hyperlipidemia. Next milestone: not disclosed (TBD).
Apremilast 20mg — phase phase_3, status completed. Indication: Psoriatic Arthritis. Next milestone: not disclosed (TBD).
Cetuximab — phase phase_3, status completed. Indication: Metastatic Colorectal Cancer. Next milestone: not disclosed (TBD).
Apremilast, Apremilast, Apremilast — phase phase_3, status active. Indication: Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).. Next milestone: not disclosed (TBD).
Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast — phase phase_3, status active. Indication: Juvenile psoriatic arthritis. Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: MariTide Phase 2 obesity data show up to 20% weight loss at one year (2026-06-07).
Nova coverage: MariTide Phase 2: Amgen reports up to 20% weight loss at one year (2026-06-07).
Nova coverage: FDA Shakeup: Høeg's Departure and Amgen Drug Controversy (2026-06-04).
Nova coverage: Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors (2026-06-02).
Nova coverage: Amgen's CFO Transition: Implications for Pharma Investments (2026-05-21).
Nova coverage: Amgen's CFO Departure and Galderma's Strategic Move (2026-05-21).
Nova coverage: Amgen's CFO Departure and Galderma's New Executive: What It Means for Pharma (2026-05-20).
Nova coverage: Amgen's Expanded Crackdown on 340B Program Misuse (2026-05-17).
Registry facts
Registry profile: founded 1980; employees 40212; market cap n/a; revenue n/a; LEI 5493007TDQLA2Z7RB387; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.800.
Catalyst calendar
Catalyst: Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow — type approval, date 2026-05-17.
Catalyst: Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors — type approval, date 2026-06-02.
Catalyst: FDA Shakeup: Høeg's Departure and Amgen Drug Controversy — type approval, date 2026-06-04.
Catalyst: MariTide Phase 2 obesity data show up to 20% weight loss at one year — type trial_data, date 2026-06-07.
Catalyst: MariTide Phase 2: Amgen reports up to 20% weight loss at one year — type trial_data, date 2026-06-07.
Competitive peers
Peer: AstraZeneca (overlap score 40.0).
Peer: AbbVie Deutschland GmbH (overlap score 40.0).
Peer: Sunshine Guojian Pharmaceutical (overlap score 40.0).
Peer: AstraZeneca (overlap score 40.0).
Peer: Summit Therapeutics (overlap score 28.2).
Peer: Esperion Therapeutics (overlap score 23.0).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.